Novel inhibitor of Cyclophilin J (CyPJ) PPIase, demonstrating remarkable inhibition of tumor cell growth, comparable to CsA but much stronger than 5-fluorouracil

Cyclooxygenase-1 inhibitor

Novel next generation orally active DPP-4 inhibitor to treat Type 2 Diabetes

Novel histone deacetylase inhibitor (HDACi) with potent oral antitumor activities

Novel histone deacetylase inhibitor (HDACi) with potent oral antitumor activities

Oral active histone deacetylase inhibitor with potent antitumor activity

Novel slow H2S-NO-releasing hybrid, attenuating cardiac dysfunction after heart failure

a STAT6 degrader for multiple immune-mediated diseases.

Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders.

1-m-PES is an electron mediator which has higher stability of solutions than 1-Methoxy PMS. The stability in neutral to alkali conditions has been extremely improved with 1-Methoxy PES. 1-M-PES is a stable small-molecular compound and it has an equal or higher thermal stability than diaphorase. The 1-Methoxy PES solution can be stored long term.

Precursor of MC1, which is a selective and potent inhibitor for COX-2, used as the radioligands for development as clinically useful PET radioligands.

MC1 is a selective and potent inhibitor for COX-2, and [11C]MC1 detected COX-2 in nonhuman primates after intracerebral injection of an inflammogen.

PT-179 is a new orthogonal immunomodulatory drug (IMiD) derivative that binds CRBN but does not induce degradation of off-target proteins. PT-179 potently degrades proteins fused to SD40 at either the N or C terminus.

UE2343 (UE-2343, Xanamem) is a potent, orally bioavailable, brain penetrant 11β-HSD1 inhibitor with IC50 of 24 nM in cell-free assays, with no activity for isozyme 11β-HSD2.

AM4085 is a potent, orally bioavailable lectin domain of FmLH antagonist with IC50 of 0.19 uM.

BB2-50F is a bactericidal inhibitor of M. tuberculosis with MIC value of 8 uM (H37Rv), inhibits succinate dehydrogenase and the F1Fo-ATP synthase.

BDM71339 is the first small molecule inhibitor of mycobacterial transcriptional regulator EthR, boosts ten times the activity of ethionamide in TB-infected macrophages at low nanomolar concentrations (EC50=72 nM) in vitro.

BDM88855 Hcl is a novel allosteric efflux-pump inhibitor that potentiate antibiotic activity in E. coli through inhibition of its primary RND transporter, AcrAB-TolC.

BDM91288 is a pyridylpiperazine-based AcrB efflux pump inhibitor, potentiate the activity of a panel of antibiotics against K. pneumoniae.

BFA1 is a specific small-molecule activator of Burkholderia FixLJ signaling pathway, inhibit the virulence of multiple pathogenic Burkholderia species.

COE2-2hexyl is a broad-spectrum antibacterial conjugated oligoelectrolyte (COE), does not evoke bacterial resistance, inhibits methicillin-resistant S. aureus (MRSA, MT3302) with MIC of 1 ug/mL.

Cresomycin (CRM) is a bridged macrobicyclic antibiotic via inhibiting bacterial ribosome, shows broad efficacy of CRM against clinical isolates of MDR Gram-negative pathogens differentiates the synthetic macrobicyclic class from traditional lincosamides.